- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hookipa Pharma Inc.
Headquarters: New York, NY, United States of America
Website: https://www.hookipapharma.com...
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Malte Peters, MD
Number Of Employees: 87
Enterprise Value: $-13,704,024
PE Ratio: -0.33
Exchange/Ticker 1: NASDAQ:HOOK
Exchange/Ticker 2: N/A
Latest Market Cap: $14,109,000
BioCentury | Jan 7, 2025
Deals
Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC
BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more
BioCentury | Jul 22, 2024
Management Tracks
Nima Farzan named CEO of Latigo
Plus: Wu Changxiong succeeds Zhou Hua as CFO of Walvax, and updates from Hookipa, Janux, Akeso and Serina
BioCentury | Jan 30, 2024
Deals
Deals roundup: Novo-EraCal in second obesity deal, Roche gives back Hookipa’s HB-700, and more
BioCentury’s weekly roundup of biopharma deals, Jan. 23-29
BioCentury | Jan 17, 2024
Management Tracks
CEO departures at Aclaris and Vaxart
Plus: David Pyrce named CEO at Cognigenics, and updates from NextPoint, Hookipa, NeoImmuneTech, Neurogene, Paratek and Aspen
BioCentury | Sep 14, 2023
Management Tracks
Gilead hires a new general manager for Korea
Plus: Character Biosciences hires Gossamer alum Laura Carter as CSO and updates from Hookipa, hC, TCB, LifeSci Partners, Evecxia
BioCentury | Jul 25, 2023
Management Tracks
Kevin Oliver named CBO at Acadia
Plus: Editas hires Linda Burkly as CSO, and updates from Bicara, Senda, Aurobac and Velia
BioCentury | Jun 8, 2023
Data Byte
May brings year’s strongest follow-on activity to date
18 biopharmas raised $2.2B, with Guardant and ImmunoGen each raising over $300M
BioCentury | Jun 1, 2023
Deals
June 1 Quick Takes: Lonza expands ADC offering with Synaffix takeout
Plus: Owkin investing $50M to build cancer spatial omics consortium and updates from Pfizer, AbbVie, Eikon, Lexicon, Hookipa, AstraZeneca, CMS and more
BioCentury | Dec 16, 2022
Management Tracks
Resilience hires Rubius, Novartis vet Fisk as CTO
Plus: Seely named president and CEO at Lyell, and updates from Codagenix, Vigil, Hookipa and Cybrexa
BioCentury | Oct 22, 2022
Deals
Roche aims to broaden KRAS efficacy in early-stage Hookipa deal
Hookipa’s immunotherapy designed to hit five KRAS mutations, create broad utility across cancer indications
Items per page:
1 - 10 of 30